在随后召开的2025北京."生命谷"医药数智化赋能生命健康之路研讨会上，与会专家聚焦"数智化赋能生 命健康"这一前沿议题，围绕人工智能助力公立医院高质量发展、AI重塑医药研发、计算医学驱动虚拟 临床试验等主题进行分享。高校、科研院所、行业协会、金融机构及企业代表参加活动。 新京报讯11月22日，以"智绘生命创领未来"为主题的生命谷(国际)生物工程创新中心启动大会暨2025北 京."生命谷"医药数智化赋能生命健康之路研讨会举行。中国卫生经济学会会长、国家卫生健康委财务 司原司长何锦国，昌平实验室党委副书记朱建红，区委书记、未来科学城党工委书记甘靖中，区委副书 记、区长，未来科学城党工委副书记、管委会主任刘晓东，北京农学院党委常委、副院长张劲柏出席。 据悉，生命谷(国际)生物工程创新中心是中国生命科学与未来产业前沿技术成果转化的战略首站，将聚 焦细胞与基因治疗、AI医疗等前沿赛道，锚定人工智能、电子信息、半导体等，形成"研发-中试-产业 化"全生命周期的生态闭环。这里汇聚全球顶尖科研资源与产业链上下游企业，依托国家级平台和临床 资源，将成为生物工程领域创新突破与成果转化的首选高地，为北京国际科技创新中心建设贡献" ...

Core Viewpoint - The seventh Pharmaceutical Frontier Academic Forum emphasizes the importance of original drug development and the role of artificial intelligence in accelerating the drug research and development process [1] Group 1: Forum Highlights - The forum, held in Nanjing, focuses on cutting-edge areas such as gene and cell therapy, advanced formulations and delivery technologies, and AI in new drug development [1] - Experts discuss the collaborative development path from source innovation to clinical transformation [1] Group 2: Key Statements - Chen Kaixian, the forum chairman and an academician of the Chinese Academy of Sciences, highlights that developing original new drugs is crucial for building new productive forces in biomedicine and achieving a strong technological nation in this field [1] - The use of artificial intelligence is noted as a key technology in drug research, with an example of an AI chemist at the University of Liverpool working 21.5 hours a day [1] - Future advancements are expected in automated molecular manufacturing, automated biological laboratories, and virtual clinical laboratories, leading to efficient and precise synthesis and continuous manufacturing of drug molecules [1]